

Takeda, OrigiMed to develop genomic based clinical treatment platform

12 November 2020 | News

With joint efforts, such a platform is believed to accelerate the R&D and commercialization of innovative medicines



OrigiMed, a China-based leading precision medicine company, and Takeda, a global biopharmaceutical company based in Japan have announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo. With joint efforts, such a platform is believed to accelerate the R&D and commercialization of innovative medicines.

Sean Shan, President of Takeda China and Senior Vice President of Takeda Pharmaceutical Company, Dr Jie Chen, Director of Department of Medicine, Takeda China, Dr Kai Wang, CEO of OrigiMed, and Ping Zhao, Vice President of OrigiMed attended the signing ceremony. Under the terms of the agreement, Takeda will bring its strength in innovative medicines development to meet Chinese patients' unmet demand for medical service.

OrigiMed will provide its "one-stop" commercialized solution by leveraging its genomic datasets and next-generation sequencing technology to accelerate innovative and precision medicines development.

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Takeda has a diverse pipeline for the innovative R&D of molecular entities focusing on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. Takeda possesses rich experiences in new drug development and commercialization. It plans to bring over 15 innovative drugs to Chinese market in the next five years, which will benefit 10 million Chinese patients. Takeda will become a multinational pharmaceutical company with the most newly marketed drugs by then.

OrigiMed, a China-based leading precision medicine company, strives to offer pharmaceutical companies integrated solutions. By utilizing big data and next-generation sequencing, OrigiMed provides comprehensive and integrated "one-stop" solutions through drug development from biomarker discovery to companion diagnosis. OrigiMed actively advocate precision medicine in China to benefit more cancer patients. OrigiMed's CLIA and CAP certified central lab provides services to many multinational pharmaceutical enterprises.